Oculis Holding AG (OCS) Form 6-K — Aug 10, 2026
Oculis Holding AG has signed an asset purchase agreement with Accure Therapeutics to acquire all of Accure's worldwide development and commercial rights to Privosegtor (ACT-01), its lead neuroprotective candidate in registrational trials for optic neuropathies, plus a second asset, ACT-02, an early-stage preclinical neurology candidate. Consideration consists of a $3.8 million (CHF 3.1 million) upfront cash payment and up to 2,050,000 Oculis ordinary shares, with upfront shares releasing from lockup over up to two years and earnout shares vesting on development and regulatory milestones.
Key figures
- Deal Value Usd
- $3.8 million upfront cash (plus up to 2,050,000 Oculis ordinary shares)
- Upfront Cash Chf
- CHF 3.1 million
- Upfront Cash Usd
- $3.8 million
- Share Consideration
- up to 2,050,000 Oculis ordinary shares
- Lockup Release Period
- upfront shares subject to lockup release over up to 2 years following deal completion
- Act02 Closing Deadline
- no later than March 31, 2027
- Ms Relapse Ind Submission
- planned Q4 2026
- Academic Institution Royalty
- low single-digit percentage royalties
- Privosegtor Closing Deadline
- no later than February 28, 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.